Candel Therapeutics (CADL) Common Equity (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Common Equity data on file, last reported at $51.9 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 21.72% year-over-year to $51.9 million; the trailing twelve-month figure through Dec 2025 stood at $51.9 million (down 21.72% YoY), and the FY2025 full-year result was $51.9 million, down 21.72% from the prior year.
• Common Equity fell to $51.9 million in Q4 2025, from $80.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $90.2 million in Q2 2025 to a low of -$43.2 million in Q2 2021.
• A 5-year average of $36.5 million and a median of $49.8 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 249.85% in 2021 and jumped 1148.95% in 2025, its largest moves.
• Tracing CADL's Common Equity over 5 years: stood at $64.1 million in 2021, then fell by 25.61% to $47.7 million in 2022, then sank by 73.29% to $12.7 million in 2023, then surged by 420.42% to $66.3 million in 2024, then fell by 21.72% to $51.9 million in 2025.
• Business Quant data shows CADL's Common Equity at $51.9 million in Q4 2025, $80.1 million in Q3 2025, and $90.2 million in Q2 2025.